{"id":"discontinue-clopidogrel","safety":{"commonSideEffects":[{"rate":"null","effect":"bleeding"},{"rate":"null","effect":"neutropenia"},{"rate":"null","effect":"thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Clopidogrel acts as an antiplatelet agent by selectively inhibiting the P2Y12 receptor, which is involved in the ADP-mediated activation of platelets. This inhibition prevents the amplification of the platelet activation process and reduces the formation of thrombi.","oneSentence":"Clopidogrel is a prodrug that is metabolized to its active form by CYP450 enzymes, primarily CYP2C19, which irreversibly inhibits platelet aggregation by blocking the P2Y12 receptor on platelets.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:10:55.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of atherothrombotic events in patients with recent myocardial infarction, recent stroke, or established peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT06650488","phase":"PHASE4","title":"Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bloodstream Infection","enrollment":300},{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT05225961","phase":"PHASE4","title":"ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-05-01","conditions":"Acute Ischemic Stroke","enrollment":240},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT07198529","phase":"NA","title":"OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina","status":"RECRUITING","sponsor":"Korea University Guro Hospital","startDate":"2025-09-30","conditions":"Stable Angina, Coronary Artery Disease","enrollment":130},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT06742931","phase":"NA","title":"Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-04-07","conditions":"Chronic Coronary Syndrome","enrollment":1200},{"nctId":"NCT07237308","phase":"PHASE4","title":"BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12","conditions":"Stroke, Ischemic, Atrial Fibrillation","enrollment":586},{"nctId":"NCT04484259","phase":"PHASE4","title":"Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-03-31","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":105},{"nctId":"NCT06742567","phase":"PHASE3","title":"Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","status":"RECRUITING","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-12-02","conditions":"Acute Myocardial Infarction of Anterior Wall, Left Ventricular Thrombus, Prophylaxis","enrollment":472},{"nctId":"NCT05955365","phase":"PHASE4","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-18","conditions":"Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation","enrollment":3010},{"nctId":"NCT02513914","phase":"NA","title":"Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial","status":"SUSPENDED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2020-06-03","conditions":"Pseudotumor Cerebri, Idiopathic Intracranial Hypertension (IIH)","enrollment":80},{"nctId":"NCT05117866","phase":"NA","title":"Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Meditrix Corp","startDate":"2020-09-15","conditions":"Chronic Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":307},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05705089","phase":"PHASE3","title":"Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI","status":"COMPLETED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2020-07-30","conditions":"Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction","enrollment":50},{"nctId":"NCT05599152","phase":"","title":"Comparison of Myocardial Infarction Patients Who Were Prescribed a Novel Antiplatelet Agent or Clopidogrel","status":"UNKNOWN","sponsor":"Chan Joon Kim","startDate":"2020-05-21","conditions":"Myocardial Infarction","enrollment":3000},{"nctId":"NCT04695106","phase":"PHASE4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2021-10-25","conditions":"Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome","enrollment":2230},{"nctId":"NCT03596060","phase":"NA","title":"Regional vs General Anesthesia in Patients With Hip Fracture Under Treatment With Clopidogrel","status":"UNKNOWN","sponsor":"Larissa University Hospital","startDate":"2017-10-20","conditions":"Hip Fractures","enrollment":150},{"nctId":"NCT03023020","phase":"NA","title":"Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2017-04-04","conditions":"High Bleeding Risk, Coronary Artery Disease, PCI","enrollment":4579},{"nctId":"NCT04995159","phase":"NA","title":"Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System","status":"NOT_YET_RECRUITING","sponsor":"Lepu Medical Technology (Beijing) Co., Ltd.","startDate":"2021-09","conditions":"Coronary Heart Disease","enrollment":2150},{"nctId":"NCT01014624","phase":"PHASE4","title":"Prasugrel/Clopidogrel Maintenance Dose Washout Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-02","conditions":"Coronary Artery Disease","enrollment":56},{"nctId":"NCT04501900","phase":"PHASE4","title":"The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-10","conditions":"Cardiovascular Diseases","enrollment":2106},{"nctId":"NCT01979445","phase":"PHASE2","title":"Cangrelor to Clopidogrel or Prasugrel Transition Study","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2013-12-02","conditions":"Coronary Artery Disease (CAD)","enrollment":15},{"nctId":"NCT02556203","phase":"PHASE3","title":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-12-16","conditions":"Transcatheter Aortic Valve Replacement","enrollment":1653},{"nctId":"NCT02696226","phase":"NA","title":"Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2016-02","conditions":"Aortic Valve Disorder","enrollment":3},{"nctId":"NCT01962545","phase":"PHASE4","title":"Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study","status":"COMPLETED","sponsor":"Satoshi Shizuta","startDate":"2013-11-05","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":690},{"nctId":"NCT00619073","phase":"NA","title":"PACT (Platelet Activity After Clopidogrel Termination)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2008-04","conditions":"Blood Platelets, Clopidogrel","enrollment":15},{"nctId":"NCT03184805","phase":"NA","title":"STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2017-06-23","conditions":"Coronary Artery Disease","enrollment":140},{"nctId":"NCT03469856","phase":"NA","title":"Acetyl Salicylic Elimination Trial: The ASET Pilot Study","status":"UNKNOWN","sponsor":"Pedro A. Lemos","startDate":"2018-02-22","conditions":"Monotherapy After PCI","enrollment":200},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":24},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT02492230","phase":"PHASE2","title":"Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2015-05","conditions":"Myocardial Infarction","enrollment":50},{"nctId":"NCT03088072","phase":"PHASE4","title":"A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure","status":"UNKNOWN","sponsor":"Scripps Health","startDate":"2017-03-23","conditions":"Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure","enrollment":75},{"nctId":"NCT01960296","phase":"PHASE2","title":"Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2012-01","conditions":"Clopidogrel","enrollment":48},{"nctId":"NCT02293928","phase":"","title":"Impact of Hybrid Coronary Revascularization on Antiplatelet Therapy","status":"COMPLETED","sponsor":"Aarhus University Hospital Skejby","startDate":"2010-10","conditions":"Coronary Artery Disease","enrollment":40},{"nctId":"NCT01156571","phase":"PHASE3","title":"A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-09","conditions":"Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":11145},{"nctId":"NCT00780156","phase":"","title":"The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel","status":"TERMINATED","sponsor":"French Cardiology Society","startDate":"2008-11","conditions":"Restenosis","enrollment":1235},{"nctId":"NCT00484926","phase":"PHASE4","title":"Association of Clopidogrel Therapy and Stent Thrombosis","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2007-03","conditions":"Coronary Artery Disease","enrollment":2000},{"nctId":"NCT01476020","phase":"","title":"Is There A LIfe for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel","status":"UNKNOWN","sponsor":"Gilard, Martine","startDate":"2011-11","conditions":"Restenosis","enrollment":1240},{"nctId":"NCT01233167","phase":"NA","title":"Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2011-08","conditions":"Coronary Artery Disease","enrollment":5232},{"nctId":"NCT00493779","phase":"PHASE4","title":"A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-10","conditions":"Antiplatelet Aggregation","enrollment":103},{"nctId":"NCT00670943","phase":"","title":"Effect of Abrupt Plavix® Discontinuation on Platelet Function","status":"COMPLETED","sponsor":"Université de Montréal","startDate":"2008-01","conditions":"Coronary Artery Disease","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Discontinue Clopidogrel","genericName":"Discontinue Clopidogrel","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopidogrel is a small molecule antiplatelet agent used to treat conditions such as myocardial infarction, chronic coronary syndrome, and left main coronary artery stenosis. It is used in conjunction with percutaneous coronary intervention, including the use of stents like the Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}